GLAUKOS Reports Strong Sales Growth Offset by $112.9M Impairment Charge and Widening Net Loss in 2025 Annual Report

summarizeZusammenfassung

Glaukos Corporation's 2025 annual report reveals a mixed financial performance, with robust net sales growth driven by new product adoption, but significantly impacted by a large impairment charge and a wider net loss. The $112.9 million impairment of the Photrexa intangible asset, triggered by the FDA approval of the new Epioxa therapy, drastically reduced the gross margin. While new product approvals like Epioxa and the re-administration of iDose TR, alongside international expansion, signal future growth potential, the immediate financial results reflect increased costs and a substantial non-cash write-down. Additionally, the company is engaged in a trade secret litigation and two executives have adopted 10b5-1 trading plans, indicating planned share sales.

check_boxSchlusselereignisse

• Annual Net Sales Increase

  Net sales grew 32% to $507.4 million in 2025, driven by a 50% increase in U.S. glaucoma product sales, primarily from iDose TR, and 18% international glaucoma sales growth.

• Significant Intangible Asset Impairment

  The company recorded a $112.9 million impairment charge on its Photrexa developed technology intangible asset due to the FDA approval and planned commercial launch of Epioxa, leading to a substantial drop in gross margin from 75% to 56%.

• Widening Net Loss

  Glaukos reported a net loss of $187.7 million in 2025, a 28% increase from $146.4 million in 2024, primarily due to the impairment charge and increased operating expenses.

• New Product Approvals and Pipeline Advancement

  Received FDA approval for Epioxa (Oct 2025) for keratoconus and for re-administration of iDose TR (Jan 2026). Also secured EU MDR certification for the iStent family, including iStent infinite, initiating European commercialization.

auto_awesomeAnalyse

Glaukos Corporation's 2025 annual report reveals a mixed financial performance, with robust net sales growth driven by new product adoption, but significantly impacted by a large impairment charge and a wider net loss. The $112.9 million impairment of the Photrexa intangible asset, triggered by the FDA approval of the new Epioxa therapy, drastically reduced the gross margin. While new product approvals like Epioxa and the re-administration of iDose TR, alongside international expansion, signal future growth potential, the immediate financial results reflect increased costs and a substantial non-cash write-down. Additionally, the company is engaged in a trade secret litigation and two executives have adopted 10b5-1 trading plans, indicating planned share sales.